US Rogosin Institute invests in MAD for Cancer
The agreement gives the cancer research at Lund University new funds. Rogosin Institute has developed a general method to stop tumor growth, and the approach is to contain the tumor cells in particles of sugar and thereby produce proteins that stops the growth of tumor cells. Rogosin Institute is involved in this cooperation with MAD for Cancer to be able to map the mechanisms underlying treatment.
- For us it is very flattering and a very good rating for cancer research in Lund, says Carl Borrebaeck, Professor at Immunotechnology and Director at CREATE Health.
It is mainly the MAD for Cancer technology for protein analysis, led by Professor Peter James, that Rogosin Institute is interested in.
- We have better equipment and more experience here in Lund than Rogosin themselves.
The first phase of the collaboration will be completed within a year and MAD for Cancer receives funding of between two and three million Swedish kronor.
- If ithis goes well, we will go on with the cooperation and the next phase gives us a much larger investment, says Carl Borrebaeck.
Professor Barry Smith, CEO of Rogosin Institute says;
– MAD for Cancer is especially attractive for Rogosin becuause of it´s multifaceted approach to cancer system biology. This is an exciting and important opportunity for cooperation since we are going to be able to further develop our cancer project through this agreement. We feel priviliged to work with the team behind MAD for Cancer.
The program MAD for Cancer was started by Carl Borrebaeck almost two years ago and brings together cancer research from four faculties at Lund University.
Read the Swedish news here.